Figure 2
From: Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
The cytotoxicity of E5 to 4T1 cells and human umbilical vein endothelial cells (HUVECs). Cells were treated with E5 at different concentrations for 24 h. The viability of 4T1 cells (a) and HUVECs (b) was measured with the CCK-8 assay. (c) The activation of caspase-3 signaling induced by E5 in 4T1 cells. A total of 3 nM vincristine was used as a positive control. (d) The apoptosis levels of cells measured by FITC-Annexin V/PI double staining. The data are presented as the means±s.d. (n=3). * represents a significant difference between the experimental groups and the untreated group (*P<0.05 and **P<0.01).
